Peter Earls Selected Research

Peter Earls Research Topics

8	Rhinosinusitis 04/2022 - 09/2012
4	Inflammation (Inflammations) 01/2022 - 02/2013
3	Eosinophilia 05/2015 - 09/2012
2	Asthma (Bronchial Asthma) 01/2022 - 09/2012
2	Neoplasms (Cancer) 01/2019 - 03/2014
1	Disease Progression 01/2019
1	Adrenocortical Carcinoma 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Ependymoma 12/2017
1	Allergic Rhinitis 01/2015
1	Hypothyroidism 01/2015
1	Hyperplasia 01/2015
1	Atrophy 01/2015
1	Xeroderma Pigmentosum (Kaposi's Disease) 03/2014
1	Melanoma (Melanoma, Malignant) 03/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2014
1	Epidermodysplasia Verruciformis 03/2014
1	Pancreatitis 02/2014
1	Hemolytic Anemia 02/2014
1	Osteitis 10/2013
1	Polyps 09/2012
1	Angiomyolipoma 05/2012
1	Perivascular Epithelioid Cell Neoplasms 05/2012
1	Paraganglioma (Paragangliomas) 10/2011
1	Pheochromocytoma 10/2011

4	CytokinesIBA 04/2022 - 02/2013
3	Biomarkers (Surrogate Marker)IBA 04/2022 - 09/2012
3	SteroidsIBA 01/2019 - 10/2013
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2015 - 09/2012
2	InterleukinsIBA 04/2022 - 05/2015
2	mepolizumabIBA 04/2022 - 01/2022
2	Biological ProductsIBA 01/2022 - 05/2012
1	Interleukin-5 (Interleukin 5)IBA 01/2022
1	benralizumabIBA 01/2022
1	Hormones (Hormone)IBA 01/2019
1	Mitotane (Lysodren)FDA Link 01/2019
1	Vitamin D FDA LinkGeneric 01/2017
1	Interleukin-33IBA 05/2015
1	Messenger RNA (mRNA)IBA 05/2015
1	Thymic Stromal LymphopoietinIBA 05/2015
1	Interleukin-17 (Interleukin 17)IBA 05/2015
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2015
1	Oncogene Proteins (Oncogene Protein)IBA 03/2014
1	CalcineurinIBA 03/2014
1	Calcineurin InhibitorsIBA 03/2014
1	Immunosuppressive Agents (Immunosuppressants)IBA 03/2014
1	Interleukin-21 ReceptorsIBA 02/2014
1	Interleukin-22 (IL-22)IBA 02/2014
1	Interleukin-2 (IL2)IBA 02/2014
1	SuperantigensIBA 01/2014
1	Chemotactic FactorsIBA 02/2013
1	Immunoglobulin E (IgE)IBA 09/2012
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2012
1	Succinate Dehydrogenase (Fumarate Reductase)IBA 10/2011